Cell Rep . Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection

[tetano]

Cell Rep


. 2020 Jul 3;107918.
doi: 10.1016/j.celrep.2020.107918. Online ahead of print.
Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection


Jinkai Wan ¹ , Shenghui Xing ¹ , Longfei Ding ² , Yongheng Wang ³ , Chenjian Gu ⁴ , Yanling Wu ⁴ , Bowen Rong ¹ , Cheng Li ⁴ , Siqing Wang ¹ , Kun Chen ¹ , Chenxi He ¹ , Dandan Zhu ⁵ , Songhua Yuan ² , Chengli Qiu ² , Chen Zhao ² , Lei Nie ⁶ , Zhangzhao Gao ⁶ , Jingyu Jiao ⁶ , Xiaoyan Zhang ⁷ , Xiangxi Wang ⁵ , Tianlei Ying ⁴ , Haibin Wang ⁶ , Youhua Xie ⁸ , Yanan Lu ⁹ , Jianqing Xu ¹⁰ , Fei Lan ¹¹



Affiliations

• PMID: 32668215
• DOI: 10.1016/j.celrep.2020.107918

Abstract

Coronavirus disease 2019 (COVID-19) has become a worldwide threat to humans, and neutralizing antibodies have therapeutic potential. We have purified more than 1,000 memory B cells specific to SARS-CoV-2 S1 or its RBD (receptor binding domain) and obtain 729 paired heavy- and light-chain fragments. Among these, 178 antibodies test positive for antigen binding, and the majority of the top 17 binders with EC₅₀ below 1 nM are RBD binders. Furthermore, we identify 11 neutralizing antibodies, eight of which show IC₅₀ within 10 nM, and the best one, 414-1, with IC₅₀ of 1.75 nM. Through epitope mapping, we find three main epitopes in RBD recognized by these antibodies, and epitope-B antibody 553-15 could substantially enhance the neutralizing abilities of most of the other antibodies. We also find that 515-5 could cross neutralize the SARS-CoV pseudovirus. Altogether, our study provides 11 potent human neutralizing antibodies for COVID-19 as therapeutic candidates.

Keywords: COVID-19; RBD; SARS-CoV-2; coronavirus; cross-neutralizing antibody; epitope; human antibodies; infection; neutralizing antibodies; spike protein.